Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Bioanalysis Year : 2022

Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods

Abstract

Background: This study compared the performance of plasma infliximab and adalimumab quantification using a commercially available kit (mAbXmise kit) and mass spectrometry readout to that of two ELISA methods in patients treated for inflammatory bowel disease. Methods and results: The mAbXmise method based on liquid chromatography tandem mass spectrometry (LC-MS/MS) was linear from 2 to 100 mu g/ml. It was validated according to international guidelines. Regarding cross-validation for infliximab (n = 70), the mean bias with LC-MS/MS assay was approximately threefold higher with the commercial ELISA assay compared with the in-house ELISA (-6.1 vs -1.8 mu g/ml, respectively). The mean bias between the LC-MS/MS assay and in-house ELISA was -1.2 mu g/ml for adalimumab (n = 35). Conclusion: The LC-MS/MS method is a powerful alternative to immunoassays to monitor concentrations of infliximab and adalimumab.
Fichier principal
Vignette du fichier
Tron_bio-2022-0057.pdf (2.57 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03714484 , version 1 (23-01-2023)

Licence

Attribution - NonCommercial - ShareAlike

Identifiers

Cite

Camille Tron, Florian Lemaitre, Pauline Bros, Claire Goulvestre, Benedicte Franck, et al.. Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods. Bioanalysis, 2022, 14 (11), pp.831-844. ⟨10.4155/bio-2022-0057⟩. ⟨hal-03714484⟩
163 View
111 Download

Altmetric

Share

Gmail Facebook X LinkedIn More